Clinical Trials · NCT03987919
A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 1,879
- Start date
- Jul 2019
- Locations
- 127 sites, 9 countries
- Primary endpoint
- Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)